Tectonic Therapeutic Files S-1

TL;DR

Tectonic Therapeutic (fka AVROBIO) filed its S-1, get ready for some biotech drama.

AI Summary

Tectonic Therapeutic, Inc. filed an S-1 form on July 19, 2024, detailing its business operations and financial status. The company, formerly known as AVROBIO, Inc., is incorporated in Delaware and operates in the biological products sector. Its principal executive offices are located in Watertown, MA.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Tectonic Therapeutic's business, financials, and future plans as it navigates the public markets.

Risk Assessment

Risk Level: medium — As a biotech company filing an S-1, Tectonic Therapeutic is likely in a pre-revenue or early-stage development phase, carrying inherent risks associated with drug development and market entry.

Key Numbers

• 20240719 — Filing Date (Date the S-1 was filed with the SEC.)
• 2024-03-31 — Quarter End Date (Represents the end of the most recent reporting quarter for financial data.)
• 2023-12-31 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• Tectonic Therapeutic, Inc. (company) — Filer of the S-1
• AVROBIO, Inc. (company) — Former name of Tectonic Therapeutic
• 2836 (dollar_amount) — Standard Industrial Classification code for Biological Products
• 03 Life Sciences (company) — Organization name associated with Tectonic Therapeutic
• 810710585 (dollar_amount) — IRS Number for Tectonic Therapeutic
• DE (company) — State of Incorporation
• MA (company) — State where business and mailing addresses are located
• 339-666-3320 (dollar_amount) — Business Phone Number

FAQ

Key Financial Figures

• $12.39908 — ck at a purchase price of approximately $12.39908 per share, for an aggregate purchase pr
• $96.6 million — gregate purchase price of approximately $96.6 million (the "Pre-Closing Financing"), and the
• $0.0001 — 9,583 shares of common stock, par value $0.0001 per share, of Tectonic Therapeutic, Inc
• $16.94 — ommon stock, as reported on Nasdaq, was $16.94 per share. See the section entitled "

Filing Documents

• d214571ds1.htm (S-1) — 4036KB
• d214571dex51.htm (EX-5.1) — 10KB
• d214571dex211.htm (EX-21.1) — 4KB
• d214571dex231.htm (EX-23.1) — 1KB
• d214571dex232.htm (EX-23.2) — 1KB
• d214571dexfilingfees.htm (EX-FILING FEES) — 17KB
• g214571g01a92.jpg (GRAPHIC) — 609KB
• g214571g01a98.jpg (GRAPHIC) — 620KB
• g214571g01b92.jpg (GRAPHIC) — 586KB
• g214571g01b98.jpg (GRAPHIC) — 608KB
• g214571g01r95.jpg (GRAPHIC) — 697KB
• g214571g01r96.jpg (GRAPHIC) — 740KB
• g214571g01r97.jpg (GRAPHIC) — 646KB
• g214571g01r99.jpg (GRAPHIC) — 613KB
• g214571g02a00.jpg (GRAPHIC) — 669KB
• g214571g02b00.jpg (GRAPHIC) — 676KB
• g214571g02r01.jpg (GRAPHIC) — 611KB
• g214571g02r05.jpg (GRAPHIC) — 664KB
• g214571g0715234928594.jpg (GRAPHIC) — 2KB
• g214571g11a01.jpg (GRAPHIC) — 29KB
• g214571g66p15.jpg (GRAPHIC) — 133KB
• 0001193125-24-181624.txt ( ) — 29496KB
• avro-20240331.xsd (EX-101.SCH) — 61KB
• avro-20240331_cal.xml (EX-101.CAL) — 61KB
• avro-20240331_def.xml (EX-101.DEF) — 209KB
• avro-20240331_lab.xml (EX-101.LAB) — 483KB
• avro-20240331_pre.xml (EX-101.PRE) — 379KB
• d214571ds1_htm.xml (XML) — 1662KB

USE OF PROCEEDS

USE OF PROCEEDS 69 MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY 70 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 71

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 85

BUSINESS

BUSINESS 101 MANAGEMENT 143

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 150 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 165 PRINCIPAL SECURITYHOLDERS 170 SELLING SECURITYHOLDERS 173

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 175 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 178 PLAN OF DISTRIBUTION 185 LEGAL MATTERS 187 EXPERTS 187 CHANGE IN CERTIFYING ACCOUNTANT 188 WHERE YOU CAN FIND MORE INFORMATION 189 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information provided in this prospectus, as well as the information incorporated by reference to exhibits to the registration statement of which this prospectus forms a part and any applicable prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling stockholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects may have changed. i Table of Contents ABOUT THIS PROSPECTUS This prospectus relates to the resale by the selling stockholders identified in this prospectus under the caption "Selling Stockholders," from time to time, of up to an aggregate of 2,969,583 shares of common stock. We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the Selling Stockholders. Neither we, nor the selling stockholders, have authorized anyone to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. The selling stockholders are offer

View Full Filing

View this S-1 filing on SEC EDGAR